Ultivue, a Cambridge, MA-based developer of reagent-driven solutions for high-performance biological imaging in situ, closed a $20m Series B funding.
The round was led by existing investor Arch Venture Partners with participation from 6 Dimensions Capital, a recent merger of WuXi Healthcare Ventures and Frontline BioVentures, Yonghua Capital, Sangel Capital, and Applied Ventures.
The company intends to use the capital to productize and commercialize its InSituPlex™ technology for unbiased biomarker analysis in tissue, at a high level of multiplex with high spatial resolution. The initial commercial focus will be in translational and clinical research markets, with a rapid transition into regulated in vitro diagnostic markets.
Founded by two core faculty from the Wyss Institute at Harvard University, David Walt, a world-leading expert in biomolecular analysis, and Peng Yin, a pioneer in DNA nanotechnology, Ultivue develops reagent-driven solutions for high-performance biological imaging in situ, combining multiplexing at high speed with high spatial resolution. The company is launching products and services that integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.